Pharmaceutical company Zafgen has secured $33 million in Series C venture funding. The financing was led by an existing investor syndicate, which includes Atlas Venture and Third Rock Ventures.
The company intends to use part of the proceeds to advance an obesity drug into Phase 2 clinical studies. Cambridge, Massachusetts-based Zafgen’s technology is designed to target imbalances in fat metabolism.
Click here for the release from Zafgen.